[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339618-105":59,"doc-detail-339618-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","asah1-facilitates-tnbc-by-dusp5-suppression-driven-activation-of-map-kinase-pathway-and-represents-a-therapeutic-vulnerability","ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability","","Triple-negative breast cancer (TNBC) is characterized by aggressive behavior, metastasis, and resistance to therapy, with limited targeted options and worse mortality than other breast cancer subtypes. To identify actionable drivers of TNBC growth and progression, the study shows N-acylsphingosine amidohydrolase 1 (ASAH1) is overexpressed in TNBC cells and is controlled by p53 and PI3K-AKT signaling. ASAH1 knockdown or inhibition suppresses TNBC progression by inducing DUSP5 and restraining the MAPK pathway, while combined ASAH1 and MAPK targeting further inhibits tumor growth.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/asah1-facilitates-tnbc-by-dusp5-suppression-driven-activation-of-map-kinase-pathway-and-represents-a-therapeutic-vulnerability/339618/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/asah1-facilitates-tnbc-by-dusp5-suppression-driven-activation-of-map-kinase-pathway-and-represents-a-therapeutic-vulnerability/339618.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does ASAH1 play in triple-negative breast cancer (TNBC)?","Question",{"text":112,"@type":113},"ASAH1 is overexpressed in TNBC cells, and inhibiting or knocking down ASAH1 suppresses TNBC growth and progression by affecting downstream signaling.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ASAH1 inhibition impact the MAPK pathway?",{"text":117,"@type":113},"ASAH1 inhibition stimulates DUSP5 expression, which suppresses the mitogen-activated protein kinase (MAPK) pathway.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the therapeutic implication of targeting ASAH1 and MAPK together?",{"text":121,"@type":113},"Pharmacological cotargeting of the ASAH1 and MAPK pathways inhibits TNBC growth, suggesting a potential dual-therapy strategy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339618,1790159756,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability  \nKiran Kumar Reddi1, Suresh Chava 1, Siva Chander Chabattula1, Yvonne J. K. Edwards 1, Kamaljeet Singh2 and Romi Gupta 1,3 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is prone to metastasis and therapy resistance. Owing to its aggressive nature and limited availability of targeted therapies, TNBC is associated with higher mortality as compared to other forms of breast cancer. In order to develop new therapeutic options for TNBC, we characterized the factors involved in TNBC growth and progression. Here, we demonstrate that N-acylsphingosine amidohydrolase 1 (ASAH1) is overexpressed in TNBC cells and is regulated via p53 and PI3K-AKT signaling pathways. Genetic knockdown or pharmacological inhibition of ASAH1 suppresses TNBC growth and progression. Mechanistically, ASAH1 inhibition stimulates dual-speciﬁcity phosphatase 5 (DUSP5) expression, suppressing the mitogen-activated protein kinase (MAPK) pathway. Furthermore, pharmacological cotargeting of the ASAH1 and MAPK pathways inhibits TNBC growth. Collectively, we unmasked a novel role of ASAH1 in driving TNBC and identiﬁed dual |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| targeting of the ASAH1 and MAPK pathways as a potential new therapeutic approach for TNBC treatment. |  |  |\n|  | Cell Death and Disease (2024)15:452; [https://doi.org/10.1038/s41419-024-06831-2](https://doi.org/10.1038/s41419-024-06831-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nTriple-negative breast cancer (TNBC) lacks hormone receptors (HR) and human epidermal growth receptors (HER2) expression and exhibits a heightened propensity for metastasis, recurrence, and signiﬁcantly reduced overall patient survival as compared with other breast cancer subtypes [1, 2]. The lack of expression of HER2 and HR receptor markers limits the availability of TNBC-targeted therapies, and current treatments rely only on standard chemotherapeutic regimens that provide limited clinical beneﬁts [3–5]. Thus, a comprehensive understanding of TNBC is imperative to develop more effective therapies to treat this breast cancer subtype.  \nCancer cells display distinct metabolic pathways to promote cell proliferation, survival, and spread [6] . Metabolic deregulation in cancer cells not only drives tumor development and progression [7, 8] but also inﬂuences the efﬁcacy and outcome of anticancer therapies [9, 10] . Deregulation of several metabolic pathways is asa key driver of cancer development and progression among different breast cancer subtypes, including TNBC [11–13] . Given the importance of metabolic enzymes and pathways in tumor development and growth, they have become promising therapeutic targets for cancer therapy [14] . Several metabolic enzyme inhibitors are currently under clinical consideration and development for the treatment of different cancer types [15] .  \nSphingolipids, a class of sphingosine-based lipids, play an important role in cell survival [14, 16, 17]. Ceramide and sphingosine, which are both interconvertible sphingolipid metabolites, are involved in cell survival [18]. Ceramide suppresses tumor growth  \nby inducing cell cycle arrest and apoptosis [19], whereas sphingosine promotes tumor growth by regulating important cancer cell processes, including angiogenesis, cell survival, proliferation, migration, and inﬂammation [20]. The maintenance of speciﬁc sphingolipid levels is critical for tumor cell growth and proliferation [21]. Ceramide level is regulated by N-acylsphingosine amidohydrolase 1 (ASAH1), an enzyme involved in ceramide metabolism [22, 23]. ASAH1 converts ceramide to sphingosine and free fatty acids, thereby creating a favorable environment for tumor growth [24]. ASAH1 express","cbCaifI1QpWUmCBV","https://ap.wps.com/l/cbCaifI1QpWUmCBV","pdf",4155072,17,"English","# Introduction\n## Background on TNBC and therapeutic limitations\n## Metabolic regulation and cancer progression\n## Sphingolipids and ASAH1 in tumor biology\n# Results\n## ASAH1 overexpression in TNBC regulated by p53 and PI3K-AKT","[{\"question\":\"What role does ASAH1 play in triple-negative breast cancer (TNBC)?\",\"answer\":\"ASAH1 is overexpressed in TNBC cells, and inhibiting or knocking down ASAH1 suppresses TNBC growth and progression by affecting downstream signaling.\"},{\"question\":\"How does ASAH1 inhibition impact the MAPK pathway?\",\"answer\":\"ASAH1 inhibition stimulates DUSP5 expression, which suppresses the mitogen-activated protein kinase (MAPK) pathway.\"},{\"question\":\"What is the therapeutic implication of targeting ASAH1 and MAPK together?\",\"answer\":\"Pharmacological cotargeting of the ASAH1 and MAPK pathways inhibits TNBC growth, suggesting a potential dual-therapy strategy.\"}]","ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability | PDF",1790031265,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44670e8525e9738bd9a568cc38be81b3.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eeee654f77aeadefdeb2072aa4010b98.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da81cfc13f8bf821ee34046e1cc0b140.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3ff298bf55d95236a5213a4411579cd.webp",980,1301]